Vanessa Chaire

440 total citations
19 papers, 315 citations indexed

About

Vanessa Chaire is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Vanessa Chaire has authored 19 papers receiving a total of 315 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Vanessa Chaire's work include Sarcoma Diagnosis and Treatment (14 papers), CAR-T cell therapy research (4 papers) and Vascular Tumors and Angiosarcomas (3 papers). Vanessa Chaire is often cited by papers focused on Sarcoma Diagnosis and Treatment (14 papers), CAR-T cell therapy research (4 papers) and Vascular Tumors and Angiosarcomas (3 papers). Vanessa Chaire collaborates with scholars based in France and Italy. Vanessa Chaire's co-authors include Antoîne Italiano, Audrey Laroche‐Clary, François Le Loarer, Marie‐Alix Derieppe, Carlo Lucchesi, Marie Karanian, Stéphanie Verbeke, Frédéric Chibon, Pauline Lagarde and Agnès Neuville and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Vanessa Chaire

17 papers receiving 315 citations

Peers

Vanessa Chaire

ONCOL

PRM

PFM

Chiara Fabbroni Italy

Maria Mihaela Mina Italy

Igor Odintsov United States

Andrej Valkov Norway

Joanna Vitfell-Rasmussen United Kingdom

Teming Zhang China

Yann Bergé France

Murtuza Rampurwala United States

Ruping Zhao China

Emmanuel Watkin France

Chiara Fabbroni Italy

Vanessa Chaire

170 ×0.9

ONCOL

117 ×0.7

PRM

86 ×0.6

43 ×0.8

20 ×0.5

PFM

Citations per year, relative to Vanessa Chaire Vanessa Chaire (= 1×) peers Chiara Fabbroni

Countries citing papers authored by Vanessa Chaire

Since Specialization

Citations

This map shows the geographic impact of Vanessa Chaire's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vanessa Chaire with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vanessa Chaire more than expected).

Fields of papers citing papers by Vanessa Chaire

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vanessa Chaire. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vanessa Chaire. The network helps show where Vanessa Chaire may publish in the future.

Co-authorship network of co-authors of Vanessa Chaire

This figure shows the co-authorship network connecting the top 25 collaborators of Vanessa Chaire. A scholar is included among the top collaborators of Vanessa Chaire based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vanessa Chaire. Vanessa Chaire is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Laroche‐Clary, Audrey, et al.. (2025). Synergistic Effects of ATR Inhibition and Lurbinectedin in Soft-Tissue Sarcomas: The Predictive Role of SLFN11 Expression. Clinical Cancer Research. 31(17). 3796–3804.

Crombé, Amandine, Carlo Lucchesi, Michèle Kind, et al.. (2024). Integration of pre-treatment computational radiomics, deep radiomics, and transcriptomics enhances soft-tissue sarcoma patient prognosis. npj Precision Oncology. 8(1). 129–129. 4 indexed citations

Verbeke, Stéphanie, et al.. (2024). Dual inhibition of BET and EP300 has antitumor activity in undifferentiated pleomorphic sarcomas and synergizes with ferroptosis induction. Translational Oncology. 52. 102236–102236. 2 indexed citations

Verbeke, Stéphanie, Jean‐Philippe Guégan, Laura Leroy, et al.. (2023). Antitumor Effects of PRMT5 Inhibition in Sarcomas. Cancer Research Communications. 3(11). 2211–2220. 1 indexed citations

Crombé, Amandine, Michèle Kind, François Le Loarer, et al.. (2022). Distinct patterns of the natural evolution of soft tissue sarcomas on pre-treatment MRIs captured with delta-radiomics correlate with gene expression profiles. European Radiology. 33(2). 1205–1218. 11 indexed citations

Toulmonde, Maud, Carlo Lucchesi, Stéphanie Verbeke, et al.. (2020). High throughput profiling of undifferentiated pleomorphic sarcomas identifies two main subgroups with distinct immune profile, clinical outcome and sensitivity to targeted therapies. EBioMedicine. 62. 103131–103131. 40 indexed citations

Laroche‐Clary, Audrey, Vanessa Chaire, Stéphanie Verbeke, et al.. (2020). ATR Inhibition Broadly Sensitizes Soft-Tissue Sarcoma Cells to Chemotherapy Independent of Alternative Lengthening Telomere (ALT) Status. Scientific Reports. 10(1). 7488–7488. 20 indexed citations

Dadone‐Montaudié, Bérengère, Audrey Laroche‐Clary, Emmanuel Chamorey, et al.. (2020). Novel Therapeutic Insights in Dedifferentiated Liposarcoma: A Role for FGFR and MDM2 Dual Targeting. Cancers. 12(10). 3058–3058. 14 indexed citations

Laroche‐Clary, Audrey, Carlo Lucchesi, Christophe Rey, et al.. (2018). CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications. Annals of Oncology. 29(4). 1023–1029. 14 indexed citations

10.

Laroche‐Clary, Audrey, et al.. (2017). Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas. Journal of Hematology & Oncology. 10(1). 123–123. 80 indexed citations

11.

Chaire, Vanessa, et al.. (2017). Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas. Journal of Hematology & Oncology. 10(1). 84–84. 23 indexed citations

12.

Chaire, Vanessa, et al.. (2017). MDM2 antagonists synergize with PI3K/mTOR inhibition in well-differentiated/dedifferentiated liposarcomas. Oncotarget. 8(33). 53968–53977. 34 indexed citations

13.

Chaire, Vanessa, Carlo Lucchesi, Marie Karanian, et al.. (2016). Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications. Oncotarget. 8(5). 7878–7890. 19 indexed citations

14.

Chaire, Vanessa, et al.. (2016). Abstract 4636: Dual targeting of PI3K/mTOR leads to MEK/ERK over-activation in leiomyosarcoma through suppression of mTORC2 inhibition. Cancer Research. 76(14_Supplement). 4636–4636. 2 indexed citations

15.

Laroche‐Clary, Audrey, et al.. (2016). Abstract 3002: The PARP inhibitor, Rucaparib enhance the sensitivity to Trabectedin in soft tissue sarcomas cell lines and in patient xenograft model. Cancer Research. 76(14_Supplement). 3002–3002. 1 indexed citations

16.

Laroche‐Clary, Audrey, Vanessa Chaire, Valérie Le Morvan, et al.. (2015). BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients. British Journal of Cancer. 112(4). 688–692. 15 indexed citations

17.

Chaire, Vanessa, Pauline Lagarde, Isabelle Hostein, et al.. (2015). Heterogeneous Mechanisms of Secondary Resistance and Clonal Selection in Sarcoma during Treatment with Nutlin. PLoS ONE. 10(10). e0137794–e0137794. 9 indexed citations

18.

Grellety, Thomas, Audrey Laroche‐Clary, Vanessa Chaire, et al.. (2015). PRIMA-1MET induces death in soft-tissue sarcomas cell independent of p53. BMC Cancer. 15(1). 684–684. 26 indexed citations

19.

Garbay, Delphine, Vanessa Chaire, Valérie Le Morvan, et al.. (2014). Predictive value of BRCA1 haplotype for trabectedin efficacy in patients with advanced soft-tissue sarcoma.. Journal of Clinical Oncology. 32(15_suppl). 10598–10598.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact